Axcella Health Inc. (AXLA): Price and Financial Metrics


Axcella Health Inc. (AXLA): $1.96

0.01 (+0.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AXLA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AXLA Stock Price Chart Interactive Chart >

Price chart for AXLA

AXLA Price/Volume Stats

Current price $1.96 52-week high $5.90
Prev. close $1.95 52-week low $1.35
Day low $1.94 Volume 31,100
Day high $1.97 Avg. volume 79,011
50-day MA $2.04 Dividend yield N/A
200-day MA $2.44 Market Cap 103.05M

Axcella Health Inc. (AXLA) Company Bio


Axcella Health Inc., a biotechnology company, researches and develops novel multifactorial interventions to support health and address dysregulated metabolism in the United States. The company develops its products based on its AXA Development Platform. It offers AXA1665 for use in treating hepatic encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic fatty liver disease; AXA2678 for use in treating immobilization-induced acute muscle atrophy; and AXA4010 to target multiple biological pathways.


AXLA Latest News Stream


Event/Time News Detail
Loading, please wait...

AXLA Latest Social Stream


Loading social stream, please wait...

View Full AXLA Social Stream

Latest AXLA News From Around the Web

Below are the latest news stories about Axcella Health Inc that investors may wish to consider to help them evaluate AXLA as an investment opportunity.

Noble Financial Thinks Axcella Health’s Stock is Going to Recover

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Axcella Health (AXLA – Research Report), with a price target of $10.00. The company's shares closed last Monday at $1.67, close to its 52-week low of $1.44. According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of 19.9% and a 33.0% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Cocrystal Pharma, and Imugene Limited. Currently, the analyst consensus on Axcella Health is a Strong Buy with an average price target of $11.75, which is a 563.8% upside from current levels.

Howard Kim on TipRanks | February 15, 2022

Axcella Health (AXLA) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Axcella Health (AXLA – Research Report) yesterday and set a price target of $14.00. The company's shares closed last Monday at $1.67, close to its 52-week low of $1.44. According to TipRanks.com, Arce is a 5-star analyst with an average return of 14.0% and a 39.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Galmed Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axcella Health with a $12.33 average price target.

Christine Brown on TipRanks | February 15, 2022

INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.

Yahoo | February 15, 2022

Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH

CAMBRIDGE, Mass., February 14, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that the U.S. Food and Drug Administration (FDA) has granted a Fast Track Designation to AXA1125 for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. AXA1125 is a multi-targeted oral drug candidate that is currently being

Yahoo | February 14, 2022

Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., February 10, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that company management will be participating in the SVB Leerink Global Healthcare Conference.

Yahoo | February 10, 2022

Read More 'AXLA' Stories Here

AXLA Price Returns

1-mo 19.51%
3-mo 8.29%
6-mo -32.41%
1-year -40.43%
3-year -86.20%
5-year N/A
YTD -6.22%
2021 -59.73%
2020 29.43%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.2137 seconds.